On this episode of "Lab Rats to Unicorns," we sit down with Julie Gilmore, Ph.D., Lilly’s vanguard in bridging the worlds of big pharma, startups, and academia. With over two decades at Lilly, Julie unpacks the role big pharma plays in scientific innovation and the multifaceted career paths and opportunities within it. We'll delve into her experiences in portfolio management, explore the nuances of life science communications, and dissect Lilly’s synergistic relationship with burgeoning startups and universities. Julie also shares her personal narrative of growth and leadership, her mentoring philosophies, and her acumen in spotting potential in the startup arena. Join us for a deep dive into the ecosystem of pharmaceuticals and the minds shaping its future. 

Julie Gilmore, Ph.D., is the Vice President and Global Head for Gateway Labs by Lilly, where she has cultivated a distinguished 20-plus-year tenure. Her journey with Lilly has seen her ascend through various leadership and scientific roles, demonstrating her versatility and expertise across research and drug development. Notable positions include her tenure as Head of Information Sciences and Clinical Operations for Lilly Europe, Global Head of Scientific Communications, and Global Head of Portfolio Management for the Neurodegeneration and Pain Early Phase Portfolio. Julie's influence extends beyond her corporate achievements; she serves on the Board of Governors for Biocom California and the Board of Directors for Mozart Therapeutics and DTx Pharma. A mentor at heart, Julie dedicates herself to guiding the next generation of scientific leaders through her involvement in several university graduate programs. Her academic credentials are equally impressive, with a doctorate in Membrane Biophysics from Purdue University and a postdoctoral fellowship in Drug Transport from Indiana University School of Medicine.